Shanghai

Zai Lab to Announce Third Quarter 2021 Financial Results

Retrieved on: 
Tuesday, October 26, 2021

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the third quarter ended September 30, 2021 after the closing of the U.S. equity markets on November 9, 2021.

Key Points: 
  • SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the third quarter ended September 30, 2021 after the closing of the U.S. equity markets on November 9, 2021.
  • The Company will host a live conference call and webcast on November 10, 2021, at 8:00 a.m.
  • A replay will be available shortly after the call and can be accessed by visiting the Company's website at http://ir.zailaboratory.com.
  • Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders and infectious disease.

Q&K Announces Disposal of WFOE

Retrieved on: 
Tuesday, October 26, 2021

The Former WFOE has a series of contractual arrangements with Shanghai Qingke E-commerce Co., Ltd, the Companys former variable interest entity, through which the Company carried out certain rental apartment operation business.

Key Points: 
  • The Former WFOE has a series of contractual arrangements with Shanghai Qingke E-commerce Co., Ltd, the Companys former variable interest entity, through which the Company carried out certain rental apartment operation business.
  • The Disposal was performed to dedicate the Companys business resources to operate higher-quality rental apartments through its subsidiaries in China.
  • As a result of the Disposal, the Company no longer conducts any operation through a variable interest entity.
  • Mr. Chengcai Qu, the chief executive officer of the Company, said, the Disposal will help us optimize our resources to focus on operating higher-quality rental apartments going forward.

Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab

Retrieved on: 
Monday, October 25, 2021

Zai Lab is excited to have dosed the first patient in the China portion of this potentially registrational Phase 2 study.

Key Points: 
  • Zai Lab is excited to have dosed the first patient in the China portion of this potentially registrational Phase 2 study.
  • Our participation in this study underscores Zais commitment to excellent execution and to bringing innovative therapeutic approaches to patients.
  • The global study is a Phase 2, open-label, multi-cohort clinical trial of odronextamab monotherapy in patients with B-NHL who have relapsed after, or are refractory to, systemic therapy.
  • Secondary objectives include safety and tolerability, complete response rate, progression-free survival, overall survival, duration of response, and disease control rate.

Users of Chinese Video Platform Bilibili Send Special Bullet Chats in Memory of Russian Creator Passed Away of COVID-19

Retrieved on: 
Friday, October 22, 2021

The video is covered with special bullet chats in Russian sent from Bilibili users in memory of uploader Pavlovs Drinking Food (referred to as Pavlov below), who passed away of COVID-19 in Russia earlier this October.

Key Points: 
  • The video is covered with special bullet chats in Russian sent from Bilibili users in memory of uploader Pavlovs Drinking Food (referred to as Pavlov below), who passed away of COVID-19 in Russia earlier this October.
  • When users send bullet chats such as farewell or rest in peace in Chinese in the memorial video made by Pavlovs Chinese friend, the bullet chats can automatically change into , which means rest in peace in Russian.
  • The views of the memorial video Farewell, Uncle Pavlov surpassed three million in just two days with over 10,000 comments.
  • Over 70,000 bullet chats have been sent by Bilibili users who are mourning for Pavlov.

UT Austin Department of Design announces six new faculty hires

Retrieved on: 
Thursday, October 21, 2021

The new UT faculty bring expertise in a range of topics, from artificial intelligence to health design and technology.

Key Points: 
  • The new UT faculty bring expertise in a range of topics, from artificial intelligence to health design and technology.
  • "I am beyond thrilled to welcome this incredibly talented group of new faculty to the Department of Design," said Kate Canales, Chair of the Department of Design in the School of Design and Creative Technologies.
  • "From traditional graphic design and interaction design to speculative product design and decolonized design history, this cohort of faculty reflects our commitment to meeting the needs of our students in these times of progress, and matriculating the future of our field."
  • In August, together with UT Robotics, the Department of Design will expand into 12,000 additional square feet of the historic Anna Hiss Gymnasium.

ECMOHO Limited Announces Partnership with Vision Care Brand Bausch + Lomb for Sales & Marketing on Pinduoduo

Retrieved on: 
Thursday, October 21, 2021

Through the partnership, ECMOHO provide consumer and Chinese family with high-quality eye care products and family health solution to satisfy the rising demand for eye health.

Key Points: 
  • Through the partnership, ECMOHO provide consumer and Chinese family with high-quality eye care products and family health solution to satisfy the rising demand for eye health.
  • Bausch + Lomb has been a leading vision care company for more than 160 years, and is a global innovation leader who sets the quality standards in this field.
  • Bausch + Lomb has a rich product line, from transparent contact lenses, colored contact lenses, to contact lens care solutions, that fully meet the needs of consumers for achieving clearer vision and improvement in their quality of life.
  • Through this cooperation between ECMOHO and Bausch + Lomb on the Pinduoduo platform, ECMOHO and Bausch + Lomb will be able to empower each other with the unique strength respectively.

ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study

Retrieved on: 
Wednesday, October 20, 2021

ZL-1102 is an investigational, novel human VH antibody fragment, targeting the IL-17A cytokine and is formulated for topical use.

Key Points: 
  • ZL-1102 is an investigational, novel human VH antibody fragment, targeting the IL-17A cytokine and is formulated for topical use.
  • This study is the first demonstration of percutaneous penetration of an IL-17-directed protein and a consequential clinical response in psoriasis.
  • ZL-1102 is an investigational, novel human VH antibody fragment, targeting the IL-17A cytokine, which was generated by Crescendo Biologics proprietary Humabody VH platform.
  • Zai Lab is conducting a conference call to discuss this news on October 21 at 8 a.m. EDT.

Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial

Retrieved on: 
Tuesday, October 19, 2021

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and its partner Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from the ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.

Key Points: 
  • Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results.
  • CRAB is a global health threat, and thanks to our partnership with Zai Lab, we were able to enroll Chinese patients in our global ATTACK clinical trial.
  • The data from the ATTACK trial are robust and incredibly exciting, demonstrating positive safety and efficacy results, combined with favorable and meaningful clinical cure rates.
  • The global Phase 3 registrational ATTACK trial was initiated in April 2019 with positive Phase 3 topline data announced in October 2021.

Zai Lab Appoints Scott Morrison to its Board of Directors

Retrieved on: 
Monday, October 18, 2021

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE,Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited(NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company,today announced that it has appointed Scott Morrison to its Board of Directors.

Key Points: 
  • SHANGHAI, SAN FRANCISCO, and CAMBRIDGE,Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited(NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company,today announced that it has appointed Scott Morrison to its Board of Directors.
  • During his tenure at EY, he worked on hundreds of public and private financings, M&A transactions, and corporate collaborations.
  • Im very pleased to have Scott join our board at this important time in Zai Labs history, said Dr.Samantha Du, Founder, Chairperson and Chief Executive Officer ofZai Lab.
  • Its an honor to join the Zai Lab Board, and I look forward to working with Samantha and her team to help Zai Lab realize its vision of becoming a leading global biopharma company.

Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences

Retrieved on: 
Friday, October 15, 2021

For more information, please contact your Jefferies representative.

Key Points: 
  • For more information, please contact your Jefferies representative.
  • One-on-one and small group meetings: November 1 - 3, 2021
    For more information, please contact your Citi representative.
  • Gracell Biotechnologies Inc.("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies.
  • For more information on Gracell, please visit www.gracellbio.com